These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 35393854)

  • 1. Generation of a Porcine Antibody Fab Fragment Using Protein Engineering to Facilitate the Evaluation of Ocular Sustained Delivery Technology.
    Kelley RF; Tesar DB; Wang Y; Agard NJ; Holder PG; Chan J; Comps-Agrar L; Horvath J; Horvath JD; Crowell SR
    Mol Pharm; 2022 May; 19(5):1540-1547. PubMed ID: 35393854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Mechanistic Model of the Intravitreal Pharmacokinetics of Large Molecules and the Pharmacodynamic Suppression of Ocular Vascular Endothelial Growth Factor Levels by Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration.
    Hutton-Smith LA; Gaffney EA; Byrne HM; Maini PK; Schwab D; Mazer NA
    Mol Pharm; 2016 Sep; 13(9):2941-50. PubMed ID: 26726925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Theoretical Insights into the Retinal Dynamics of Vascular Endothelial Growth Factor in Patients Treated with Ranibizumab, Based on an Ocular Pharmacokinetic/Pharmacodynamic Model.
    Hutton-Smith LA; Gaffney EA; Byrne HM; Caruso A; Maini PK; Mazer NA
    Mol Pharm; 2018 Jul; 15(7):2770-2784. PubMed ID: 29734810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors That Can Prolong Ocular Treatment Duration in Age-Related Macular Degeneration.
    Kaiser PK; Giani A; Fuchs H; Chong V; Heier JS
    Ophthalmic Res; 2023; 66(1):653-663. PubMed ID: 36626895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. End-of-Study Results for the Ladder Phase 2 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration.
    Khanani AM; Callanan D; Dreyer R; Chen S; Howard JG; Hopkins JJ; Lin CY; Lorenz-Candlin M; Makadia S; Patel S; Tam T; Gune S;
    Ophthalmol Retina; 2021 Aug; 5(8):775-787. PubMed ID: 33217618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration.
    Holekamp NM; Campochiaro PA; Chang MA; Miller D; Pieramici D; Adamis AP; Brittain C; Evans E; Kaufman D; Maass KF; Patel S; Ranade S; Singh N; Barteselli G; Regillo C;
    Ophthalmology; 2022 Mar; 129(3):295-307. PubMed ID: 34597713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonclinical Toxicology and Biocompatibility Program Supporting Clinical Development and Registration of the Port Delivery System With Ranibizumab for Neovascular Age-Related Macular Degeneration.
    Bantseev V; Horvath J; Barteselli G; Ranade S; Maia M; Yadav DB; Schuetz C; Shelton A; Booler HS
    Toxicol Pathol; 2021 Apr; 49(3):663-672. PubMed ID: 33205714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe Ocular Inflammation Following Ranibizumab or Aflibercept Injections for Age-Related Macular Degeneration: A Retrospective Claims Database Analysis.
    Souied EH; Dugel PU; Ferreira A; Hashmonay R; Lu J; Kelly SP
    Ophthalmic Epidemiol; 2016; 23(2):71-9. PubMed ID: 26855278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An efficacy analysis of anti-vascular endothelial growth factor therapy for choroidal neovascularization secondary to multifocal choroiditis and comparison with wet age-related macular degeneration.
    Feng L; Hu JH; Chen J; Xie X
    J Zhejiang Univ Sci B; 2018 Apr.; 19(4):327-332. PubMed ID: 29616508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wet age-related macular degeneration: treatment advances to reduce the injection burden.
    Baumal CR
    Am J Manag Care; 2020 May; 26(5 Suppl):S103-S111. PubMed ID: 32479026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term follow-up of vascular endothelial growth factor inhibitor therapy for neovascular age-related macular degeneration.
    Scott AW; Bressler SB
    Curr Opin Ophthalmol; 2013 May; 24(3):190-6. PubMed ID: 23492430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular endothelial growth factor in patients with exudative age-related macular degeneration treated with ranibizumab.
    Muether PS; Hermann MM; Viebahn U; Kirchhof B; Fauser S
    Ophthalmology; 2012 Oct; 119(10):2082-6. PubMed ID: 22920670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
    Veloso CE; Kanadani TM; Pereira FB; Nehemy MB
    Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial.
    Zehetner C; Kralinger MT; Modi YS; Waltl I; Ulmer H; Kirchmair R; Bechrakis NE; Kieselbach GF
    Acta Ophthalmol; 2015 Mar; 93(2):e154-9. PubMed ID: 25488124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical efficacy and safety of ranibizumab in the treatment of wet age-related macular degeneration.
    Ferro Desideri L; Barra F; Ferrero S; Traverso CE; Nicolò M
    Expert Opin Biol Ther; 2019 Aug; 19(8):735-751. PubMed ID: 31180279
    [No Abstract]   [Full Text] [Related]  

  • 16. Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis.
    Ba J; Peng RS; Xu D; Li YH; Shi H; Wang Q; Yu J
    Drug Des Devel Ther; 2015; 9():5397-405. PubMed ID: 26451092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein engineering to increase the potential of a therapeutic antibody Fab for long-acting delivery to the eye.
    Tesar D; Luoma J; Wyatt EA; Shi C; Shatz W; Hass PE; Mathieu M; Yi L; Corn JE; Maass KF; Wang K; Dion MZ; Andersen N; Loyet KM; van Lookeren Campagne M; Rajagopal K; Dickmann L; Scheer JM; Kelley RF
    MAbs; 2017; 9(8):1297-1305. PubMed ID: 28854082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP).
    Rofagha S; Bhisitkul RB; Boyer DS; Sadda SR; Zhang K;
    Ophthalmology; 2013 Nov; 120(11):2292-9. PubMed ID: 23642856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aflibercept in wet AMD: specific role and optimal use.
    Semeraro F; Morescalchi F; Duse S; Parmeggiani F; Gambicorti E; Costagliola C
    Drug Des Devel Ther; 2013; 7():711-22. PubMed ID: 23990705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fellow Eye Comparisons for 7-Year Outcomes in Ranibizumab-Treated AMD Subjects from ANCHOR, MARINA, and HORIZON (SEVEN-UP Study).
    Bhisitkul RB; Desai SJ; Boyer DS; Sadda SR; Zhang K
    Ophthalmology; 2016 Jun; 123(6):1269-77. PubMed ID: 26996339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.